76 related articles for article (PubMed ID: 3945117)
21. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
[TBL] [Abstract][Full Text] [Related]
23. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
[TBL] [Abstract][Full Text] [Related]
25. Interaction of bisantrene anti-cancer agents with DNA: footprinting, structural requirements for DNA unwinding, kinetics and mechanism of binding and correlation of structural and kinetic parameters with anti-cancer activity.
Elliott JA; Wilson WD; Shea RG; Hartley JA; Reszka K; Lown JW
Anticancer Drug Des; 1989 Mar; 3(4):271-82. PubMed ID: 2539168
[TBL] [Abstract][Full Text] [Related]
26. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro.
Drewinko B; Yang LY; Barlogie B; Trujillo JM
Cancer Res; 1983 Jun; 43(6):2648-53. PubMed ID: 6850582
[TBL] [Abstract][Full Text] [Related]
27. [Hemodynamics in the territory of balloon occluded internal iliac artery--problems of balloon occluded arterial infusion therapy for urinary bladder cancer].
Sugai Y; Hosoya T; Yamaguchi K; Kubota Y
Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Sep; 52(9):1258-72. PubMed ID: 1437531
[TBL] [Abstract][Full Text] [Related]
28. Novel Software-Assisted Hemodynamic Evaluation of Pelvic Flow During Chemoperfusion of Pelvic Arteries for Bladder Cancer: Double- Versus Single-Balloon Technique.
Yamamoto K; Yamamoto K; Nakai G; Azuma H; Narumi Y
Cardiovasc Intervent Radiol; 2016 Jun; 39(6):824-30. PubMed ID: 26817759
[TBL] [Abstract][Full Text] [Related]
29. [Collaterals after flow alternation in pelvic arteries: precondition for pelvic reservoir therapy].
Nasu K; Fujimoto H; Yamamoto S; Naitou H; Maekawa I; Yasuda S; Itou H
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Apr; 58(5):204-11. PubMed ID: 9617155
[TBL] [Abstract][Full Text] [Related]
30. Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.
Onishi H; Yamaguchi M; Kuriyama K; Tsukamoto T; Ishigame K; Ichikawa T; Aoki S; Yoshikawa T; Araki T; Nambu A; Araki T; Hashi A; Yasumizu T; Hoshi K; Ito H
Cancer J Sci Am; 2000; 6(1):40-5. PubMed ID: 10696738
[TBL] [Abstract][Full Text] [Related]
31. [Studies of intra-arterial hypertensive chemotherapy with cisplatin and peplomycin in advanced cancer of the uterine cervix--suitable dose of angiotensin II determined by intra-arterial digital subtraction angiography].
Iwanari O; Date Y; Nakayama S; Miyako J; Kijima S; Moriyama M; Yamamoto K; Takahashi K; Iida K; Kitao M
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):835-40. PubMed ID: 2458418
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of internal iliac arterial infusion of platinum compounds in a rabbit cervical cancer model.
Itamochi H; Kigawa J; Minagawa Y; Cheng X; Okada M; Terakawa N
Obstet Gynecol; 1997 Feb; 89(2):286-90. PubMed ID: 9015037
[TBL] [Abstract][Full Text] [Related]
33. An in vitro flow model to study streaming during pelvic intra-arterial drug infusions.
Lutz RJ; Epstein AH; Cook JA; Dedrick RL
Gynecol Oncol; 1995 Nov; 59(2):288-96. PubMed ID: 7590489
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
[TBL] [Abstract][Full Text] [Related]
35. Ultra-low-dose intra-arterial contrast injection for iliofemoral computed tomographic angiography.
Joshi SB; Mendoza DD; Steinberg DH; Goldstein MA; Lopez CF; Raizon A; Weissman G; Satler LF; Pichard AD; Weigold WG
JACC Cardiovasc Imaging; 2009 Dec; 2(12):1404-11. PubMed ID: 20083076
[TBL] [Abstract][Full Text] [Related]
36. Recurrent cervical cancer in the pelvis--intra-arterial infusion of oncostatics.
Kawagoe K; Iijima S; Sasaki J
Jpn J Clin Oncol; 1983 Dec; 13(4):673-81. PubMed ID: 6196500
[TBL] [Abstract][Full Text] [Related]
37. Intra-arterial infusion therapy following alteration of pelvic blood flow and concurrent radiation therapy for invasive bladder cancer.
Umeyama T; Mashimo T; Nakazato H; Tokunaga T; Uehara H; Shinozaki T; Kawashima M; Akimoto T
Int J Urol; 1996 Jan; 3(1 Suppl):S44-5. PubMed ID: 24304022
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein mediates profound resistance to bisantrene.
Zhang XP; Ritke MK; Yalowich JC; Slovak ML; Ho JP; Collins KI; Annable T; Arceci RJ; Durr FE; Greenberger LM
Oncol Res; 1994; 6(7):291-301. PubMed ID: 7865904
[TBL] [Abstract][Full Text] [Related]
39. Bisantrene in relapsed and refractory acute myelogenous leukemia.
Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
[TBL] [Abstract][Full Text] [Related]
40. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
